Join us to explore the latest best practices in global flow cytometry QC and harmonisation. During this webinar hosted by Bioanalysis Zone ICON’s flow cytometry specialists will discuss: - Industry best practices for h...

In recognition of Rare Disease Day, join ICON’s Centre for Rare Diseases for an inspiring panel at our upcoming webinar on 3 March at 11 am EST. Hear directly from parent and patient leaders whose advocacy is driving f...

The EU Joint Clinical Assessment is already influencing how oncology therapies are developed and assessed across Europe. In this article, Dr. Liz O’Brien of ICON explains how #JCA is driving earlier evidence generation, ...

Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a...

Flow cytometry is rapidly evolving - driven by high parameter and spectral technologies, smarter data analytics and global standardisation efforts. This Spotlight hosted by Bioanalysis Zone brings together leading expe...

Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. This article in SelectScience® explores the evolving NIT landscape, emerging regulat...

In this Journal of mHealth article, Ashish Koul explains how open-source R software empowers CROs to modernise statistical workflows, cut costs and deliver more transparent, scalable analyses. Read more: https://ow.ly/Q1...

New analyses show that well-implemented DHTs can: - Reduce trial timelines by 3–5 months - Decrease enrollment requirements by up to 16% - Lower protocol amendment risk - Deliver meaningful ROI in both Phase II and Phase...

Patient led organisations are shaping scientific and regulatory strategy in ultra rare diseases. Join our live panel as we bring together leaders whose work has contributed to gene therapies, accelerated approvals and ...